NASDAQ:RLAY

Relay Therapeutics (RLAY) Stock Forecast, Price & News

$8.41

+0.17 (+2.06%)

(As of 09/29/2023 ET)

Compare

Today's Range: $8.16
▼
$8.55
50-Day Range: $8.24
▼
$12.60
52-Week Range: $7.82
▼
$24.17

Volume: 882,617 shs
Average Volume: 1.12 million shs
Market Capitalization: $1.03 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $26.06

Relay Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 209.8% Upside
$26.06 Price Target
Short Interest: Bearish
23.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.16
Based on 3 Articles This Week
Insider Trading: Selling Shares
$43,825 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.28) to ($3.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

895th out of 972 stocks

Biological Products, Except Diagnostic Industry

145th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Relay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.06, Relay Therapeutics has a forecasted upside of 209.8% from its current price of $8.41.
Amount of Analyst Coverage
Relay Therapeutics has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
23.71% of the float of Relay Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Relay Therapeutics has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.
Change versus previous month
Short interest in Relay Therapeutics has recently increased by 0.96%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Relay Therapeutics does not currently pay a dividend.
Dividend Growth
Relay Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RLAY.

2.9

News and Social Media Coverage

News Sentiment
Relay Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Relay Therapeutics this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for RLAY on MarketBeat in the last 30 days.
MarketBeat Follows
5 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,825.00 in company stock.
Percentage Held by Insiders
Only 3.54% of the stock of Relay Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Relay Therapeutics are expected to decrease in the coming year, from ($3.28) to ($3.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Relay Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Relay Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Relay Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

RLAY Price History

30 days | 90 days | 365 days | Advanced Chart

RLAY Stock News Headlines

September 24, 2023 | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages

September 18, 2023 | finance.yahoo.com

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 1, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 9, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ansell (OtherANSLF) and Relay Therapeutics (RLAY)

August 9, 2023 | msn.com

Oppenheimer Reiterates Relay Therapeutics (RLAY) Outperform Recommendation

August 8, 2023 | finance.yahoo.com

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

August 8, 2023 | finance.yahoo.com

Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights

August 1, 2023 | finance.yahoo.com

Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023

October 1, 2023 | Stansberry Research (Ad)

U.S. "Shadow Banks" About to Blow up again?

Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.

July 28, 2023 | seekingalpha.com

Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608

July 3, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Relay Therapeutics (RLAY), Bright Health Group (BHG) and Bausch + Lomb Corporation (BLCO)

June 10, 2023 | msn.com

HC Wainwright & Co. Maintains Relay Therapeutics (RLAY) Buy Recommendation

June 9, 2023 | msn.com

11 Analysts Have This to Say About Relay Therapeutics

June 5, 2023 | markets.businessinsider.com

Barclays Sticks to Its Hold Rating for Relay Therapeutics (RLAY)

May 18, 2023 | finance.yahoo.com

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Deliver On Growth Plans?

May 12, 2023 | seekingalpha.com

Relay Therapeutics May 2023 Corporate Presentation

May 9, 2023 | seekingalpha.com

Relay Therapeutics: Selloff On Poor Breast Cancer Data May Have Been Overblown

May 9, 2023 | markets.businessinsider.com

Berenberg Bank Sticks to Their Buy Rating for Relay Therapeutics (RLAY)

May 5, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Relay Therapeutics (RLAY)

May 4, 2023 | msn.com

Relay Therapeutics: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates

May 3, 2023 | msn.com

Earnings Outlook For Relay Therapeutics

April 26, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY) and CureVac (CVAC)

April 20, 2023 | msn.com

Stifel Maintains Relay Therapeutics (RLAY) Buy Recommendation

April 20, 2023 | msn.com

Jefferies Upgrades Relay Therapeutics (RLAY)

April 20, 2023 | markets.businessinsider.com

What 11 Analyst Ratings Have To Say About Relay Therapeutics

April 20, 2023 | finance.yahoo.com

4 big analyst picks: BofA ups composite decking stocks Azek, Trex | Pro Recap

See More Headlines

Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLAY Company Calendar

Last Earnings: 8/08/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RLAY
CUSIP: N/A
CIK: 1812364
Web: www.relaytx.com
Phone: 617-370-8837
Fax: N/A
Employees: 345
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $26.06
High Stock Price Forecast: $34.00
Low Stock Price Forecast: $12.50
Forecasted Upside/Downside: +209.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-290,510,000.00
Net Margins: -36,562.53%
Pretax Margin: -36,562.53%
Return on Equity: -37.81%
Return on Assets: -32.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.35
Quick Ratio: 12.36

Sales & Book Value

Annual Sales: $1.38 million
Price / Sales: 744.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.86 per share
Price / Book: 1.07

Miscellaneous

Outstanding Shares: 122,130,000
Free Float: 117,810,000
Market Cap: $1.03 billion
Optionable: Not Optionable
Beta: 1.38

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Alexis A. Borisy A.M. (Age 51)
Co-Founder & Independent Chairman
Comp: $85k

Dr. Sanjiv K. Patel M.A. (Age 49)
M.B.A., M.D., MBBS, CEO, Pres & Director
Comp: $1.03M

Dr. Mark Murcko Ph.D. (Age 63)
Co-Founder & Director
Comp: $50k

Mr. Thomas Catinazzo (Age 46)
Chief Financial Officer
Comp: $599.83k

Mr. Brian R. Adams J.D. (Age 49)
Chief Legal Officer & Sec.
Comp: $598.53k

Dr. Donald A. Bergstrom M.D. (Age 51)
Ph.D., Pres of R&D
Comp: $711.25k

Mr. Peter Rahmer
Chief Corp. Devel. Officer

Dr. Deborah Palestrant Ph.D.
VP of Corp. Devel. & Strategy

Mr. Jim Watters Ph.D.
Chief Scientific Officer of Late Research

Dr. Beni B. Wolf M.D.
Ph.D., Chief Medical Officer & Head of Precision Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RLAY Stock - Frequently Asked Questions

Should I buy or sell Relay Therapeutics stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RLAY shares.
View RLAY analyst ratings or view top-rated stocks.
What is Relay Therapeutics' stock price forecast for 2023?: 10 brokerages have issued 12-month target prices for Relay Therapeutics' stock. Their RLAY share price forecasts range from $12.50 to $34.00. On average, they expect the company's stock price to reach $26.06 in the next twelve months. This suggests a possible upside of 209.8% from the stock's current price.
View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts.
How have RLAY shares performed in 2023?: Relay Therapeutics' stock was trading at $14.94 on January 1st, 2023. Since then, RLAY shares have decreased by 43.7% and is now trading at $8.41.
View the best growth stocks for 2023 here.
When is Relay Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RLAY earnings forecast.
How were Relay Therapeutics' earnings last quarter?: Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its earnings results on Tuesday, August, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.03. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.81 million. Relay Therapeutics had a negative net margin of 36,562.53% and a negative trailing twelve-month return on equity of 37.81%. The firm's revenue for the quarter was down 67.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.71) earnings per share.
What ETFs hold Relay Therapeutics' stock?: ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), Range Cancer Therapeutics ETF (CNCR) and SPDR S&P Biotech ETF (XBI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Relay Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).
When did Relay Therapeutics IPO?: (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO.
What is Relay Therapeutics' stock symbol?: Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."
How do I buy shares of Relay Therapeutics?: Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Relay Therapeutics' stock price today?: One share of RLAY stock can currently be purchased for approximately $8.41.
How much money does Relay Therapeutics make?: Relay Therapeutics (NASDAQ:RLAY) has a market capitalization of $1.03 billion and generates $1.38 million in revenue each year. The company earns $-290,510,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis.
How many employees does Relay Therapeutics have?: The company employs 345 workers across the globe.
How can I contact Relay Therapeutics?: Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.relaytx.com. The company can be reached via phone at 617-370-8837 or via email at prahmer@relaytx.com.

This page (NASDAQ:RLAY) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial